We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Screening laboratories can use these template letters to contact clinicians about a presumed positive newborn screening result for inherited metabolic diseases.
How to apply for a clinical trial including eligibility, phases, model IMPDs, costs and how to make changes to your application.
This publication contains information on local sites (ie sites designated locally for their substantive nature conservation importance, either for wildlife or geology). These sites are being managed so as to preserve their nature conservation interest (ie. are in “positive conservation...
Apply for changes to your marketing authorisation, including minor variations type IA and IB, major variations type II and extensions.
Data about positivity after COVID-19 vaccination from the COVID-19 Infection Survey. This survey is being delivered in partnership with University of Oxford, University of Manchester, Public Health England and Wellcome Trust. This study is jointly led by the ONS and...
Guidance on conditional marketing authorisations, exceptional circumstances marketing authorisations and national scientific advice.
Guidance for Applicants wishing to apply for a Promising Innovative Medicines designation, pre-submission meeting or an EAMS Scientific Opinion.
Information on the progress of projects in the Government Major Projects Portfolio.
International collaboration establishes new quality standards to improve reliability of gut health studies – improving accuracy to provide better diagnosis and treatment.
The MHRA’s Interim Executive Director of Science and Research writes in The British Medical Journal on the approval of the UK’s first new UTI antibiotic in nearly 30 years, and the wider challenge of tackling antibiotic resistance.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).